Board of Directors

Tim Harkness

President and Chief Executive Officer

Tim joined ProteinSimple as President and CEO in June 2008, and has more than 18 years of leadership experience in the life sciences industry. Tim spent over 9 years as CFO at Molecular Devices where he helped grow the company's revenue from $38M to $185M through internal growth and acquisitions before successfully selling the company for over $600M. Early in his career, Tim helped raise over $1B for life sciences companies in the public equity markets as a Health Care Investment Banker at Montgomery Securities. Mr. Harkness currently serves on the Board of Directors at Accelrys, a scientific software company, at Freeslate, a private high-throughput research company and as Chairman of ALDA, the Analytical Life Sciences and Diagnostic Tools Industry Association. Mr. Harkness holds an M.B.A. from Stanford University Graduate School of Business and a B.B.A from the University of Wisconsin. Tim is married with 3 children, enjoys barefoot running, golfing, and is an avid sports fan.

A. Blaine Bowman


Mr. Bowman was most recently the President and Chief Executive Officer of Dionex Corporation (NASDAQ: DNEX), a leading developer and manufacturer of laboratory and process analytical systems and related products. Mr. Bowman joined the company in 1977. Under his leadership, Dionex grew from $1 million in sales to over $180 million and is widely respected for its innovative products and solid growth. Earlier, he was a management consultant with McKinsey and Company and a product engineer in Motorola Semiconductor Products Division. Mr. Bowman holds a B.S. Degree in Physics from Brigham Young University and an M.B.A. from Stanford University Graduate School of Business. Additionally, Mr. Bowman has served on the Board of Directors of Molecular Devices Corporation since 1992.

David L. Barker, Ph.D.

Dr. David L. Barker currently serves on the Boards of Directors of ProteinSimple, BIoNanomatrix, Integrated Diagnostics, IntegenX Inc., and NextBio, and is a scientific advisor to Illumina, GenVault, Diagnostics for the Real World, Helixis, BiOptix, and DNA Direct. He was Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 through 2006. Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.

In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a B.S. with honors in Chemistry from the California Institute of Technology and a Ph.D. in Biochemistry from Brandeis University.

Ron Eastman

Essex Woodlands Health Ventures

Ron Eastman has over 30 years of experience in building healthcare businesses. He began his career at American Cyanamid Company where Mr. Eastman spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then, he has helped build three private healthcare companies — Geron, HCORP, and Rinat Neuroscience.

Under his leadership, Geron became a cutting-edge biotech company which grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. Most recently, at Rinat, a private biotech company spun out of Genentech in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer in 2006.

Mr. Eastman joined Essex Woodlands in October 2006. In addition to the portfolio company boards on which he serves, Mr. Eastman serves on the Board of Directors for the Juvenile Diabetes Research Foundation and on the Board of Trustees at The Buck Institute, the largest non-profit research institute in the U.S. studying aging-related diseases.

Joe Keegan, Ph.D.

Dr. Keegan brings more than 30 years of experience managing high growth life science businesses. Most recently, he served as the CEO of ForteBio where he transformed the company from a startup in 2007 to a fast growing leader in label-free protein analysis. ForteBio was acquired in 2012 by Pall Corporation. Previously, Dr. Keegan was the CEO of Molecular Devices (MDC). During his 9-year tenure at MDC, Dr. Keegan grew the company's revenue from $30 million to $185 million, at which point the company was sold to MDS, Inc. for $615 million. Prior to MDC, Dr. Keegan served as President of Worldwide Tissue Culture of Becton Dickinson and Vice President of Microscope and Scientific Instruments Division of Leica. He currently serves on the Board of Directors of ALDA as Immediate Past Chairman, Advanced Cell Diagnostics, Labcyte Corporation as Chairman, Response Biomedical Corp, Seahorse Bioscience Inc., Stereotaxis, Inc. and the San Francisco Opera. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

Jack Nielsen

Novo Ventures

Jack Nielsen is Partner in Novo Ventures, which he joined in 2001. From 1990 to 2001 Mr. Nielsen held various positions in the Novo Nordisk business area, which in 2000 became Novozymes A/S. The last four years before joining Novo Ventures he was deeply involved in designing the research and development strategy for the company's efforts in the Cereal Food area, resulting in the development and launch of novel recombinant lipase and amylase enzymes. Mr. Nielsen was previously involved in collaborations with Procter & Gamble, Danisco, and Quest International to identify new enzymes for the detergent and cereal food industry. He held positions in marketing and technical services in the textile and personal care area, and started his career in the field of large-scale manufacturing of enzymes. Mr. Nielsen serves on the boards of directors of ProteinSimple, Inc., Protein Forest, Inc. and Reata Pharmaceuticals, Inc., and he is a former director of Panacos Pharmaceuticals, Inc., Nuevolution A/S, and CardioOptics, Inc.

Jack Nielsen obtained his M.Sc. in 1990 from the Technical University of Denmark, and his Master in Management of Technology from the Center for Technology, Economics and Management in Copenhagen in 2000.

Chris van Ingen

Mr. van Ingen has over two decades of senior management leadership experience and has served as an advisor to many life science companies. Most recently as President of Agilent Technologies' Bio-Analytical Measurement business, he oversaw the growth of that business from $1 billion to over $2 billion in annual revenues in less than 6 years. Mr. van Ingen currently serves on the Board of Directors of Bruker EST, Inc., Accelrys, Inc., as Chairman, and Promega Corporation. In addition, Mr. van Ingen serves as a strategic consultant to several companies in the Life Sciences and Chemical Analysis instrumentation industry. He previously served as a Director of Alpha Innotech Corporation and Symyx Technologies, Inc. until its merger with Accelrys in July 2010. Mr. van Ingen holds a B.S. degree in analytical chemistry.

Jim Woody, Ph.D.

Latterell Venture Partners

Dr. Woody brings more than 25 years of biomedical research and management experience to LVP. Dr. Woody was formerly President of Roche Bioscience in Palo Alto, California where he had responsibility for all bioscience research and development, ranging from genetics and genomics to clinical development. Previously, Dr. Woody served as Chief Scientific Officer and Senior Vice President of Research & Development for Centocor, where he was responsible for the discovery and early clinical development of antibody and peptide-based therapeutic products. While at Centocor, Dr. Woody developed Remicade®, the first of the TNF inhibitor biologics, as well as ReoPro®, a novel platelet blocking drug used in conjunction with angioplasty. Prior to Centocor, Dr. Woody served as Commanding Officer and Director, U.S. Naval Medical Research and Development Command in Bethesda, Maryland. In that role, he was responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the U.S. Navy Legion of Merit for his service. Dr. Woody holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England.